CD274 and cancer: Their results are similar to data from KEYNOTE-028 (9–33% response rate), which evaluated the safety and efficacy of pembrolizumab alone in patients with PD-L1-positive advanced solid tumors.397 Nevertheless, investigators should consider these data carefully because the tumor areas excluded from the SBRT program are exposed to low doses of RT and there is a lack of PD-L1 status for patients with various cancers.